Belly Fat-Melting Jab Is Now One Step Away From FDA Approval
20th July 2025
What if you could inject a drug into a “problem area” – like abdominal fat – that could kill off fat cells and reduce fat stores in that localized spot? That’s what a novel drug from Taiwan’s Caliway Pharmaceuticals offers, the world’s very first injection that triggers programmed fat-cell death in a targeted area, like the belly or the thighs.
Known as CBL-514, this small-molecule drug induces adipocyte apoptosis, which kills fat cells rather than starves them, meaning different regions of subcutaneous fat stores can be rapidly reduced in just a few weeks after a single dose. It’s currently being tested for three uses: Non-surgical fat reduction, Dercum’s disease – which causes painful fatty tumors to build up around the body, and cellulite.
“Administered via subcutaneous injection, CBL-514 has demonstrated a favorable safety and tolerability profile, enabling significant localized fat reduction without surgery and delivering results comparable to liposuction,” Caliway has stated.
While it’s being investigated for various applications, the leading one – and the one expected to be on the market first – is for the non-surgical reduction of problematic abdominal fat.
And, in about twenty years, we’ll discover that it has some appalling side effects.